ProCE Banner Activity

CME

Exploring New Treatment Strategies for Immune Checkpoint Blockade in Melanoma

Multimedia
In this on-demand Webcast from a live symposium from AACR 2019, expert faculty examine the use of immune checkpoint inhibitors in the adjuvant and neoadjuvant settings for patients with melanoma.

Physicians: Maximum of 1.75 AMA PRA Category 1 Credits

Released: June 21, 2019

Expiration: June 20, 2020

No longer available for credit.

Share

Faculty

Michael B. Atkins

Michael B. Atkins, MD

Professor of Medicine
Harvard Medical School
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Rodabe Amaria

Rodabe Amaria, MD

Assistant Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Ahmad Tarhini

Ahmad Tarhini, MD, PhD

Assistant Professor of Medicine
Department of Medicine/Hematology-Oncology
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Merck Oncology

Target Audience

This activity is intended for oncologists and other healthcare professionals involved in the treatment of melanoma.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan optimal adjuvant treatment strategies for patients with melanoma at high risk of recurrence after surgical resection based on available data and expert recommendations
  • Evaluate the available clinical data on neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
  • Manage adverse events effectively in patients receiving novel targeted agents or immunotherapies for melanoma based on available data, recommendations, and available decision support tools
  • Identify patients with advanced melanoma suitable for enrollment on ongoing clinical studies investigating novel therapies or combination strategies

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Michael B. Atkins, MD

Professor of Medicine
Harvard Medical School
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Michael B. Atkins, MD, has disclosed that he has received funds for research support (paid to his institution) from Bristol-Myers Squibb, Genentech, Merck, and Pfizer; has received consulting fees from Acceleron, Aduro, Alexion, Amgen, Array, AstraZeneca, Aveo, Boehringer Ingelheim, Bristol-Myers Squibb, Cota, Genentech/Roche, Eisai, Exelixis, Idera, Immunocore, Iovance, Lynx, Merck, NewLink, Novartis, Pfizer, and Surface; has served on advisory boards for Arrowhead, Bristol-Myers Squibb, Fathom, Glactone, Merck, Novartis, Pfizer, and Werewolf; and has stock options in Werewolf.

Faculty Disclosure

Primary Author

Rodabe Amaria, MD

Assistant Professor
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Rodabe Amaria, MD, has disclosed that she has received funds for research support from Array, Bristol-Myers Squibb, Genentech, Iovance, and Merck.

Ahmad Tarhini, MD, PhD

Assistant Professor of Medicine
Department of Medicine/Hematology-Oncology
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Ahmad Tarhini, MD, PhD, has disclosed that he has received funds for research support from Bristol-Myers Squibb, Genentech/Roche, Idera, Incyte, Merck, and Novartis and consulting fees from Array, Bristol-Myers Squibb, EMD Serono/Pfizer, Genentech/Roche, HUYA, Immunocore, Incyte, Merck, NewLink, Novartis, and Sanofi Genzyme/Regeneron.

Staff Disclosure

Staff

Elaine S. DeMeyer, MSN, RN, AOCN

Editorial Contributor

Elaine S. DeMeyer, MSN, RN, AOCN, has no relevant conflicts of interest to report.

Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 21, 2019, through June 20, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to educate physicians and other healthcare professionals about advances in the clinical management of patients with melanoma.